Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy

Experimental and Clinical Psychopharmacology

Volumn 14, Issue 1, 2006, Pages 42-51

  Lindner, Mark D ^a   Bourin, Clotilde ^a   Chen, Ping ^a   McElroy, John F ^a   Leet, John E ^a   Hogan, John B ^a   Stock, David A ^a   Machet, Frederic ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

Adverse effects; Cognitive deficits; Painful diabetic neuropathy; Streptozotocin

Indexed keywords

AMITRIPTYLINE; GABAPENTIN;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; LOW DRUG DOSE; MALE; MOBILIZATION; MOTOR DYSFUNCTION; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; STREPTOZOCIN DIABETES;

AMINES; AMITRIPTYLINE; ANIMALS; COGNITION DISORDERS; CYCLOHEXANECARBOXYLIC ACIDS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; MALE; MAZE LEARNING; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; STREPTOZOCIN;

EID: 33644591441     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.14.1.42     Document Type: Article

References (49)

1. Abdi, S., Lee, D. H., & Chung, J. M. (1998). The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesthesia and Analgesia, 87, 1360-1366.
2. Backonja, M., Beydoun, A., Edwards, K. R., Schwartz, S. L., Fonseca, V., Hes, M., et al. (1998). Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: A randomized controlled trial. JAMA, 280, 1831-1836.
3. Backonja, M., & Glanzman, R. L. (2003). Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials. Clinical Therapeutics, 25, 81-104.
4. Boyce, S., Wyatt, A., Webb, J. K., O'Donnell, R., Mason, G., Rigby, M., et al. (1999). Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: Correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology, 38, 611-623.
5. Brunbech, L., & Sabers, A. (2002). Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: A comparative review of newer versus older agents. Drugs, 62, 593-604.
6. Calcutt, N. A. (2002). Future treatments for diabetic neuropathy: Clues from experimental neuropathy. Current Diabetes Reports, 2, 482-488.
7. Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., & Yaksh, T. L. (1994). Quantitative assessment of tactile allodynia in the rat paw. Journal of Neuroscience Methods, 53, 55-63.
8. Chapman, C. R. (1995). The affective dimension of pain: A model. In B. Bromm & J. E. Desmedt (Eds.), Pain and the brain (pp. 283-301). Philadelphia: Lippincott-Raven.
9. Courteix, C., Bardin, M., Chantelauze, C., Lavarenne, J., & Eschalier, A. (1994). Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain, 57, 153-160.
10. Courteix, C., Eschalier, A., & Lavarenne, J. (1993). Streptozocin-induced diabetic rats: Behavioural evidence for a model of chronic pain. Pain, 53, 81-88.
11. Dworkin, R. H., Backonja, M., Rowbotham, M. C., Allen, R. R., Argoff, C. R., Bennett, G. J., et al. (2003). Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations. Archives of Neurology, 60, 1524-1534.
12. Esser, M. J., Chase, T., Allen, G. V., & Sawynok, J. (2001). Chronic administration of amitriptyline and caffeine in a rat model of neuropathic pain: Multiple interactions. European Journal of Pharmacology, 430, 211-218.
13. Esser, M. J., & Sawynok, J. (1999). Acute amitriptyline in a rat model of neuropathic pain: Differential symptom and route effects. Pain, 80, 643-653.
14. Field, M. J., Gonzalez, M. I., Tallarida, R. J., & Singh, L. (2002). Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. Journal of Pharmacology and Experimental Therapeutics, 303, 730-735.
15. 2δ subunit of voltage dependent calcium channels in models of neuropathic pain. British Journal of Pharmacology, 131, 282-286.
16. Field, M. J., McCleary, S., Hughes, J., & Singh, L. (1999). Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain, 80, 391-398.
17. Fisher, R. S., Sachdeo, R. C., Pellock, J., Penovich, P. E., Magnus, L., & Bernstein, P. (2001). Rapid initiation of gabapentin: A randomized, controlled trial. Neurology, 56, 743-748.
18. Follett, K. A., Hitchon, P. W., Piper, J., Kumar, V., Clamon, G., & Jones, M. P. (1992). Response of intractable pain to continuous intrathecal morphine: A retrospective study. Pain, 49, 21-25.
19. Fordyce, W. E., Lansky, D., Calsyn, D. A., Shelton, J. L., Stolov, W. C., & Rock, D. L. (1984). Pain measurement and pain behavior. Pain, 18, 53-69.
20. Galer, B. S., Gianas, A., & Jensen, M. P. (2000). Painful diabetic polyneuropathy: Epidemiology, pain description, and quality of life. Diabetes Research and Clinical Practice, 47, 123-128.
21. Hanner, C. J., Hill, S. A., Taylor, M. J., Cowen, P. J., & Goodwin, G. M. (2003). Toward a neuropsychological theory of antidepressant drug action: Increase in positive emotional bias after potentiation of norepinephrine activity. American Journal of Psychiatry, 160, 990-992.
22. Hermann, N., Lanctot, K., & Myszak, M. (2000). Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. Journal of Clinical Psychopharmacology, 20, 90-93.
23. Hofmann, H. A., De Vry, J., Siegling, A., Spreyer, P., & Denzer, D. (2003). Pharmacological sensitivity and gene expression analysis of the tibial nerve injury model of neuropathic pain. European Journal of Pharmacology, 470, 17-25.
24. Johansen, J. P., Fields, H. L., & Manning, B. H. (2001). The affective component of pain in rodents: Direct evidence for a contribution of the anterior cingulate cortex. Proceedings of the National Academy of Sciences, USA, 98, 8077-8082.
25. Kayser, V., & Christensen, D. (2000). Antinociceptive effect of systemic gabapentin in mononeuropathic rats, depends on stimulus characteristics and level of test integration. Pain, 88, 53-60.
26. King, H., Aubert, R. E., & Herman, W. H. (1998). Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care, 21, 1414-1431.
27. Knutson, B., Cole, S., Wolkowitz, O., Reus, V., Chan, T., & Moore, E. (1997). Serotonergic intervention increases affiliative behavior in humans. Annals of the New York Academy of Sciences, 807, 492-493.
28. Knutson, B., Wolkowitz, O. M., Cole, S. W., Chan, T., Moore, E. A., Johnson, R. C., et al. (1998). Selective alteration of personality and social behavior by serotonergic intervention. American Journal of Psychiatry, 155, 373-379.
29. Lindner, M. D., Plone, M. A., Francis, J. M., & Cain, C. K. (1999). Chronic morphine reduces pain-related disability in a rodent model of chronic, inflammatory pain. Experimental and Clinical Psychopharmacology, 7, 187-197.
30. Martin, R., Meador, K., Turrentine, L., Faught, E., Sinclair, K., Kuzniecky, R., et al. (2001). Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults. Epilepsia, 42, 764-771.
31. Max, M. B. (1995). Antidepressant drugs as treatments for chronic pain: Efficacy and mechanisms. In B. Bromm & J. E. Desmedt (Eds.), Pain and the brain: From nociception to cognition (pp. 501-515). New York: Lippincott-Raven.
32. Max, M. B., Culnane, M., Schafer, S. C., Gracely, R. H., Walther, D. J., Smoller, B., et al. (1987). Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology, 37, 589-596.
33. Meador, K. J., Loring, D. W., Ray, P. G., Murro, A. M., King, D. W., Nichols, M. E., et al. (1999). Differential cognitive effects of carbamazepine and gabapentin. Epilepsia, 40, 1279-1285.
34. Mellegers, M. A., Furlan, A. D., & Mailis, A. (2001). Gabapentin for neuropathic pain: Systematic review of controlled and uncontrolled literature. Clinical Journal of Pain, 17, 284-295.
35. Milliken, G. A., & Johnson, D. E. (1992). Analysis of messy data: Vol. 1. Designed experiments. New York: Van Nostrand Reinhold.
36. Morello, C. M., Leckband, S. G., Stoner, C. P., Moorhouse, D. F., & Sahagian, G. A. (1999). Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Archives of Internal Medicine, 159, 1931-1937.
37. Morris, R. G. M. (1981). Spatial localization does not require the presence of local cues. Learning and Motivation, 12, 239-260.
38. National Research Council. (1996). Guide for the care and use of laboratory animals. Washington, DC: National Academy Press.
39. Parsons, B., Tive, L., & Huang, S. (2004). Gabapentin: A pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. American Journal of Geriatric Pharmacotherapy, 2, 157-162.
40. Patel, S., Naeem, S., Kesingland, A., Froestl, W., Capogna, M., Urban, L., et al. (2001). The effects of GABA(B) agonists and gabapentin on mechanical hyperalgesia in models of neuropathic and inflammatory pain in the rat. Pain, 90, 217-226.
41. Penn, R. D., & Paice, J. A. (1987). Chronic intrathecal morphine for intractable pain. Journal of Neurosurgery, 67, 182-186.
42. Price, D. D. (2000, June 9). Psychological and neural mechanisms of the affective dimension of pain. Science, 288, 1769-1772.
43. Salinsky, M. C., Binder, L. M., Oken, B. S., Storzbach, D., Aron, C. R., & Dodrill, C. B. (2002). Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers. Epilepsia, 43, 482-490.
44. Sanders, S. H. (1983). Automated versus self-monitoring of "up-time" in chronic low-back pain patients: A comparative study. Pain, 15, 399-405.
45. Schmader, K. E. (2002). Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clinical Journal of Pain, 18, 350-354.
46. Twycross, R. G. (1974). Clinical experience with diamorphine in advanced malignant disease. International Journal of Clinical Pharmacology, Therapy and Toxicology, 9, 184-198.
47. Yasuda, T., Iwamoto, T., Ohara, M., Sato, S., Kohri, H., Noguchi, K., et al. (1999). The novel analgesic compound OT-7100 (5-n-butyl-7-(3,4,5- trimethoxybenzoylamino)pyrazolo[1,5-a] pyrimidine) attenuates mechanical nociceptive responses in animal models of acute and peripheral neuropathic hyperalgesia. Japanese Journal of Pharmacology, 79, 65-73.
48. Young, M. J., Boulton, A. J., MacLeod, A. F., Williams, D. R., & Sonksen, P. H. (1993). A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia, 36, 150-154.
49. Zimmermann, M. (1983). Ethical guidelines for investigators of experimental pain in conscious animals. Pain, 16, 109-110.